
ACTU Stock Forecast & Price Target
ACTU Analyst Ratings
Bulls say
Actuate Therapeutics is a promising clinical stage biopharmaceutical company with a positive outlook due to their focus on developing targeted therapies for high-impact, difficult to treat cancers. Their lead candidate, elraglusib, has shown activity in preclinical pediatric models and has the potential for a short clinical development timeline with regulatory alignment. Additionally, their diverse pipeline and potential eligibility for a Priority Review Voucher upon approval in orphan oncology indications make Actuate a strong investment opportunity.
Bears say
Actuate Therapeutics is currently facing significant financial challenges with no revenues and consistently reporting net losses, leading to a pessimistic outlook on its stock performance. Additionally, the company's cash reserves are not sufficient to fund future operations, putting it at risk of potential bankruptcy. Furthermore, while the development of oral elraglusib remains a potential value driver, it may not be sufficient to offset the company's financial struggles and risks associated with clinical, manufacturing, and regulatory factors.
This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ACTU Analyst Forecast & Price Prediction
Start investing in ACTU
Order type
Buy in
Order amount
Est. shares
0 shares